Investors

Mindset is developing next-generation psychedelic medicines and related manufacturing processes to help treat neuropsychiatric patients with unmet needs.

Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:
Lead Compound MSP-1014 demonstrating superior preclinical characteristics in head-to-head comparison with psilocybin
4 patent-pending new drug families drawing on novel chemical structures;
Over 75 compounds synthesized with preclinical data demonstrating promising results; and
Synthesis process for psilocybin demonstrating clear benefits over known processes.

Download Presentation

Press Releases & News

Mindset Pharma Announces Inclusion in NYSE Listed AdvisorShares Psychedelics Exchange Traded Fund (ETF)

September 23, 2021

Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018

September 20, 2021

Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay

September 14, 2021

Upcoming Events

No items found.

Analyst Coverage

Firm

Maxim Group LLC

Analyst

Jason McCarthy, Ph.D.

Mindset Pharma Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Mindset Pharma Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Mindset Pharma Inc. or its management. Mindset Pharma Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.